We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues ‘Streamlined’ Nonclinical Trial Guidance for Hematologic Disorder Drugs
FDA Issues ‘Streamlined’ Nonclinical Trial Guidance for Hematologic Disorder Drugs
The FDA released draft guidance on a “streamlined nonclinical program” for sponsors of nonclinical studies for development of pharmaceuticals for treatment of patients with debilitating or life-threatening hematologic disorders, saying such nonclinical studies should consider general toxicology, pharmacology and reproductive toxicology.